After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...